Applied Health Economics and Health Policy

Papers
(The TQCC of Applied Health Economics and Health Policy is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Cost-Effectiveness of Perinatal Depression Screening: A Scoping Review114
Assessing the Direct Impact of Death on Discrete Choice Experiment Utilities62
Cost-Effectiveness and Value of Information Analyses of Caplacizumab for the Treatment of Thrombotic Thrombocytopenic Purpura in Brazil38
Therapy, Pills and Unmet Needs for Financial Reasons: Socioeconomic Inequalities and Inequities in Access to Mental Health Care in Spain 2014–202036
Deterministic and Probabilistic Analysis of a Simple Markov Model: How Different Could They Be?36
Cost-Effectiveness of a Universal School-Based Mental Health Prevention Program: An Economic Modeling Study in a Limited Income Context32
Approaches to Incorporation of Preferences into Health Economic Models of Genomic Medicine: A Critical Interpretive Synthesis and Conceptual Framework32
Cost-Effective and Sustainable Drug Use in Hospitals: A Systematic and Practice-Based Approach28
Cost-Effectiveness Analysis of Evolocumab or Inclisiran in Combination with Statins Versus Statin Monotherapy Among Patients with ASCVD in China26
Population Norms for SF-6Dv2 and EQ-5D-5L in China23
A Guideline-Implementation Intervention to Improve the Management of Low Back Pain in Primary Care: A Difference-in-Difference-in-Differences Analysis22
Psychometric Evaluation of the PedsQL GCS and CHU9D in Australian Children and Adolescents with Common Chronic Health Conditions20
Selection and Prioritization of Medical Devices for HTA Evaluation: A Systematic Review of Existing Approaches19
Correction to: The Cost Effectiveness of Taxation of Sugary Foods and Beverages: A Systematic Review of Economic Evaluations19
Applications of Behavioral Economics to Pharmaceutical Policymaking: A Scoping Review with Implications for Best-Value Biological Medicines19
Economic Evaluation of Evusheld for Preexposure Prevention of COVID-19 in High-Risk Populations: Early Evidence from Thailand18
Avoiding Opportunity Cost Neglect in Cost-Effectiveness Analysis for Health Technology Assessment17
The Effect of Price Changes and Teaspoon Labelling on Intention to Purchase Sugar-Sweetened Beverages: A Discrete Choice Experiment17
Exploratory Approach to Incorporating Carbon Footprint in Health Technology Assessment (HTA) Modelling: Cost-Effectiveness Analysis of Health Interventions in the United Kingdom17
A Systematic Review of the World’s Largest Government Sponsored Health Insurance Scheme for 500 Million Beneficiaries in India: Pradhan Mantri Jan Arogya Yojana16
Financing Comprehensive Immunization Services in Lao PDR: A Fiscal Space Analysis From a Public Policy Perspective16
Local Level Economic Evaluation: What is it? What is its Value? Is it Sustainable?15
Correction to: Cost Effectiveness of Allogeneic Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Patients with Knee Osteoarthritis14
How is Value Defined in Molecular Testing in Cancer? A Scoping Review14
Economic Evaluation Evidence for Resource-Allocation Decision Making: Bridging the Gap for Local Decision Makers Using English Case Studies14
The Economic Cost of Rising Non-communicable Diseases in India: A Systematic Literature Review of Methods and Estimates14
10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?14
Economic Effects of Fixed-Dose Versus Loose-Dose Combination Therapy for Type 2 Diabetes Patients13
Including Pharmaceuticals in Bundled Payments13
Scope Issue in Contingent Valuation Studies of the COVID-19 Vaccine: The Case of China13
Correction: Deterministic and Probabilistic Analysis of a Simple Markov Model: How Different Could They Be?13
Estimating the Health Effects of Expansions in Health Expenditure in Indonesia: A Dynamic Panel Data Approach13
How Much Should be Invested in Lung Care Across the WHO European Region? Applying a Monetary Value to Disability-Adjusted Life-Years Within the International Respiratory Coalition’s Lung Facts12
Social Costs of Smoking in the Czech Republic11
Development of a Health Technology Assessment Quality Appraisal Checklist (HTA-QAC) for India10
Budget Impact Analysis of the Introduction of Subcutaneous Infliximab (CT-P13 SC) for the Treatment of Rheumatoid Arthritis in the United Kingdom10
Contextual Factors that Influence Antibiotic Prescribing: A Discrete Choice Experiment of GP Registrars10
Valuation of Costs in Health Economics During Financial and Economic Crises: A Case Study from Lebanon10
Indirect and Direct Mapping of the Cancer-Specific EORTC QLQ-C30 onto EQ-5D-5L Utility Scores10
Measures of Performance and Clinical Superiority Thresholds for ‘Test-and-treat’ Predictive Biomarkers9
Is Economic Evaluation and Care Commissioning Focused on Achieving the Same Outcomes? Resource-Allocation Considerations and Challenges Using England as a Case Study9
Does the Choice of Health Metric, DALY or QALY, Influence Conclusions of Health Economic Evaluation? A Case Study of Rotavirus Vaccine in Burundi9
The Impact of Unrelated Future Medical Costs on Economic Evaluation Outcomes for Different Models of Diabetes9
Guiding Health Resource Allocation: Using Population Net Health Benefit to Align Disease Burden with Cost Effectiveness for Informed Decision Making9
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations9
Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy9
Correction to: Different Frameworks, Similar Results? Head-to-Head Comparison of the Generic Preference-Based Health-Outcome Measures CS-Base and EQ-5D-5L9
A Systematic Review of Cost-Effectiveness Analyses of Colorectal Cancer Screening in Europe: Have Studies Included Optimal Screening Intensities?9
Cost-Effectiveness and Budget Impact Analysis of Implementing a 'Soft Opt-Out' System for Kidney Donation in Australia9
Machine Learning-Assisted Health Economics and Policy Reviews: A Comparative Assessment8
Effect of Competition on Generic Drug Prices8
Willingness to Pay for National Health Insurance: A Contingent Valuation Study Among Patients Visiting Public Hospitals in Melaka, Malaysia8
Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland8
Trump’s Drug Pricing Order and the Domestic Economic Trade-Off8
Comparing Preferences for Disease Profiles: A Discrete Choice Experiment from a US Societal Perspective8
Young People’s Preferences for Web-Based Mental Health Interventions for Managing Anxiety and Depression: A Discrete Choice Experiment8
Cost-Effectiveness of Anti-retroviral Adherence Interventions for People Living with HIV: A Systematic Review of Decision Analytical Models8
Projected Impact on Labour Productivity Costs of Cancer-Related Premature Mortality in Europe 2018–20408
Herd Immunity Effects in Cost-Effectiveness Analyses among Low- and Middle-Income Countries8
The Health Economics of Genomic Technologies: A Growing Evidence Base on Value7
Use of Cost-Effectiveness Thresholds in Healthcare Public Policy: Progress and Challenges7
Productivity Loss and Indirect Costs for Patients Newly Diagnosed with Early- versus Late-Stage Cancer in the USA: A Large-Scale Observational Research Study7
Analysing the Efficiency of Health Systems: A Systematic Review of the Literature7
Measurement of Catastrophic Health Expenditure in India: A Systematic Review and Meta-Analysis7
Societal Cost of Racial Pneumococcal Disease Disparities in US Adults Aged 50 Years or Older7
The Effects of School Closures on COVID-19: A Cross-Country Panel Analysis7
Forecasting the Incremental Value to Society Created by a Class of New Prescription Drugs: A Proposed Methodology and Its Application to Treating Chronic Hepatitis C in India7
The Broader Opportunity Costs in the Broader Cost-Effectiveness Analysis Framework7
Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting7
Information Asymmetry in Hospitals: Evidence of the Lack of Cost Awareness in Clinicians7
Sedaconda ACD-S for Sedation with Volatile Anaesthetics in Intensive Care: A NICE Medical Technologies Guidance7
Discrete Event Simulation in R using the ‘Simmer’ Package for Health Economic Modelling: A Tutorial and Illustration in Colon Cancer6
From Spreadsheets to Script: Experiences From Converting a Scottish Cardiovascular Disease Policy Model into R6
Exploring Consumer Preferences for Cannabis Vaping Products to Support Public Health Policy: A Discrete Choice Experiment6
The Limitations and Potentials of Evaluating Economic Aspects of Community-Based Health Promotion: A Critical Review6
Estimating a Drug’s Price After Loss of Exclusivity as a Function of Its Cost of Goods Sold6
Estimated Carbon Savings from Changing Surgical Trends in Primary Elective Total Hip Arthroplasty in England: A Retrospective Observational Study6
Headroom Analysis for Early Economic Evaluation: A Systematic Review6
Cost-effectiveness Analysis of the Dental RECUR Pragmatic Randomized Controlled Trial: Evaluating a Goal-oriented Talking Intervention to Prevent Reoccurrence of Dental Caries in Children6
EQ-5D-5L Population Norms for Italy6
The Impact of Value-Based Payment Models for Networks of Care and Transmural Care: A Systematic Literature Review6
A Head-On Comparison of EQ-VT- and Crosswalk-Based EQ-5D-5L Value Sets6
0.053133010864258